Trial Profile
A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2024
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ODENZA; ODENZA Preference
- 01 Mar 2024 Primary endpoint has not been met (Patient preference), as per Results published in the European Urology
- 01 Mar 2024 Results published in the European Urology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology